Opus Genetics
IRD
33 hedge funds and large institutions have $6.23M invested in Opus Genetics in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
6% less funds holding
Funds holding: 35 → 33 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
38% less capital invested
Capital invested by funds: $10.1M → $6.23M (-$3.83M)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$2.31M |
| 2 |
Renaissance Technologies
New York
|
+$213K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$99.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$46.6K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$8.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CL
CSS LLC
Chicago,
Illinois
|
-$5.21M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$33K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$17.5K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$11.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5.32K |
IRD Hedge Fund Activity: Q3 2016 in Review
33 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Opus Genetics (IRD) for Q3 2016, worth a combined $6.23M — down 38% from $10.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IRD and 2 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $2.31M. The largest seller was CSS LLC, exiting entirely with an estimated $5.21M sold.
- 33 institutional investors held Opus Genetics (IRD) as of Q3 2016, down from 35 in Q2 2016.
- Funds reported $6.23M of Opus Genetics stock for Q3 2016, down 38% quarter-over-quarter.
- 2 funds opened new Opus Genetics positions in Q3 2016 and 4 closed out, a net change of -2 holders.
- The largest Opus Genetics buyer in Q3 2016 was Anson Funds Management, an estimated $2.31M added.
- The largest Opus Genetics seller in Q3 2016 was CSS LLC, an estimated $5.21M sold.
Based on aggregated 13F filings for Q3 2016.